First report on the targeted therapy of an IDH1-mutated Cholangiocarcinoma in a patient with Maffucci syndrome

被引：0
|
作者：
Peters, M. [1 ]
Lessel, D. [2 ]
Bernreuther, C. [3 ]
Iglauer, P. [3 ]
Heukamp, L. [4 ]
Velthaus, J. -L. [1 ]
Bokemeyer, C. [1 ]
Sonja, L. [1 ]
Volk, A. [2 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 2, Hamburg, Germany
[2] Univ Klinikum Hamburg Eppendorf, Inst Humangenet, Hamburg, Germany
[3] Univ Klinikum Hamburg Eppendorf UKE, Hamburg, Germany
[4] Inst Hamatopathol Hamburg, Hamburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
426
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [31] EvIDHence study: Treatment patterns, duration of treatment and safety outcomes of patients with IDH1-mutated and wild-type cholangiocarcinoma
    Melisi, D.
    Lamarca, A.
    Blanc, J. F.
    Perkhofer, L.
    Gharbi, H.
    Robert, R.
    Sahai, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S126 - S126
  • [32] IDH1-mutated relapsed or refractory AML: current challenges and future prospects
    Eduardo Megias-Vericat, Juan
    Ballesta-Lopez, Octavio
    Barragan, Eva
    Montesinos, Pau
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 19 - 32
  • [33] Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma
    Chmielewska, Agnieszka
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (04): : 286 - 290
  • [34] Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
    Rimini, Margherita
    Burgio, Valentina
    Antonuzzo, Lorenzo
    Rimassa, Lorenza
    Oneda, Ester
    Solda, Caterina
    Cito, Pasqua
    Nasti, Guglielmo
    Lavacchi, Daniele
    Zanuso, Valentina
    Rizzato, Mario Domenico
    Zaniboni, Alberto
    Ottaiano, Alessandro
    Persano, Mara
    Cornara, Noemi
    Scartozzi, Mario
    Cascinu, Stefano
    Casadei-Gardini, Andrea
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [35] MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES
    Verheul, Cassandra
    Kers, Trisha
    Van der Kaaij, Marielle
    Pierson, Tessa
    Gao, Ya
    Dirven, Clemens
    Struys, Eduard
    Salomons, Gajja
    Leenstra, Sieger
    French, Pim
    Lamfers, Martine
    NEURO-ONCOLOGY, 2018, 20 : 274 - 274
  • [36] IMPAIRED PARP1 DNA REPAIR DEFINES CHEMOSENSITIVITY IN IDH1-MUTATED CELL
    Lu, Yanxin
    Liu, Yang
    Gilbert, Mark
    Wu, Jing
    Yang, Chunzhang
    NEURO-ONCOLOGY, 2018, 20 : 102 - 102
  • [37] STAT5 Signaling Promotes Resistance to Ivosidenib in IDH1-Mutated AML
    Liu, Alex
    Cathelin, Severine
    Chan, Steven M.
    BLOOD, 2021, 138
  • [38] Profiling the metabolic effects of AGI-5198 treatment on IDH1-mutated gliomas
    Rodado, Victor Ruiz
    Lita, Adrian
    Dowdy, Tyrone
    Gilbert, Mark R.
    Larion, Mioara
    CANCER RESEARCH, 2017, 77
  • [39] Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
    Rimini, Margherita
    Burgio, Valentina
    Antonuzzo, Lorenzo
    Rimassa, Lorenza
    Oneda, Ester
    Solda, Caterina
    Cito, Pasqua
    Nasti, Guglielmo
    Lavacchi, Daniele
    Zanuso, Valentina
    Rizzato, Mario Domenico
    Zaniboni, Alberto
    Ottaiano, Alessandro
    Persano, Mara
    Cornara, Noemi
    Scartozzi, Mario
    Cascinu, Stefano
    Casadei-Gardini, Andrea
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [40] Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Valle, J.
    Abou-Alfa, G.
    Kelley, R.
    Lowery, M.
    Shroff, R.
    Bian, Y.
    Saint-Hilary, G.
    Liu, H.
    Teng, Z.
    Hua, Z.
    Gliser, C.
    Vogel, A.
    Javle, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S162 - S162
12345